Based in North Chicago, Illinois, AbbVie is a research-based biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical therapies across multiple therapeutic areas. The company's portfolio spans immunology, oncology, neuroscience, eye care, gastroenterology, and aesthetics. Key products include Humira (autoimmune diseases), Skyrizi (psoriasis and other autoimmune conditions), Rinvoq (inflammatory diseases), Imbruvica and Venclexta (blood cancers), Botox Therapeutic (neurologic disorders), Vraylar (psychiatric conditions), and Mavyret (hepatitis C). The company also markets eye care products such as Restasis and Lumigan, as well as gastrointestinal treatments including Linzess and Creon.
AbbVie's commercial operations extend globally, with revenues generated across pharmaceutical, biologic, and specialty medicine categories. The aesthetics division contributes through facial injectables, skincare products, and body contouring offerings. The company maintains a strategic partnership with OSE Immunotherapeutics to support its pipeline development.
As one of the largest pharmaceutical manufacturers by market capitalization, AbbVie operates manufacturing and research facilities across multiple geographies to serve worldwide markets. The company was established in 2012 as a separate entity incorporated in Delaware.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $1.02 | $1.02 | +5200.0% | |
| 2024 | $-0.02 | $-0.02 | -104.3% | |
| 2023 | $0.46 | $0.46 | -66.7% | |
| 2022 | $1.38 | $1.39 | -38.9% | |
| 2021 | $2.26 | $2.27 | +22500.0% | |
| 2020 | $0.01 | $0.01 | -99.5% | |
| 2019 | $1.88 | $1.88 | +252.8% | |
| 2018 | $-1.23 | $-1.23 | -4200.0% | |
| 2017 | $0.03 | $0.03 | -96.5% | |
| 2016 | $0.85 | $0.86 | -7.6% | |
| 2015 | $0.92 | $0.93 | +280.4% | |
| 2014 | $-0.51 | $-0.51 | -172.9% | |
| 2013 | $0.70 | $0.70 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-20 | 0001551152-26-000008 | SEC ↗ |
| 2024-12-31 | 2025-02-14 | 0001551152-25-000020 | SEC ↗ |
| 2023-12-31 | 2024-02-20 | 0001551152-24-000011 | SEC ↗ |
| 2022-12-31 | 2023-02-17 | 0001551152-23-000011 | SEC ↗ |
| 2021-12-31 | 2022-02-18 | 0001551152-22-000007 | SEC ↗ |
| 2020-12-31 | 2021-02-19 | 0001551152-21-000008 | SEC ↗ |
| 2019-12-31 | 2020-02-21 | 0001551152-20-000007 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001551152-19-000008 | SEC ↗ |
| 2017-12-31 | 2018-02-16 | 0001551152-18-000014 | SEC ↗ |
| 2016-12-31 | 2017-02-17 | 0001551152-17-000004 | SEC ↗ |